FTXH - ETF AI Analysis
Top Page
First Trust Nasdaq Pharmaceuticals ETF (FTXH)
Rating:72Outperform
Price Target:―
Positive Factors
Solid Recent Performance
The ETF has shown positive returns so far this year and in the most recent month, indicating improving momentum.
Strong Core Pharma Holdings
Several major pharmaceutical names in the top holdings, such as Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer, Viatris, and Biogen, have delivered strong year-to-date gains that support the fund’s results.
Focused Healthcare Exposure
The fund’s near-total allocation to U.S. healthcare and pharmaceuticals offers targeted exposure to a defensive sector that can be more resilient in economic slowdowns.
Negative Factors
High Sector Concentration
Almost all assets are in the healthcare sector, so the ETF is heavily exposed to swings in pharmaceutical and biotech markets.
Mixed Performance Among Top Holdings
Some large positions like AbbVie, Eli Lilly, Regeneron, and Zoetis have been weak so far this year, which can drag on overall returns if the trend continues.
Above-Average Expense Ratio
The fund’s fee is relatively high for an ETF, which means more of the gross return is lost to costs over time.
FTXH vs. SPDR S&P 500 ETF (SPY)
AUM34.55M
RegionNorth America
Expense Ratio0.60%
Beta0.56
IssuerFirst Trust
Inception DateSep 20, 2016
Dividend Yield1.21%
Asset ClassEquity
Index TrackedNasdaq US Smart Pharmaceuticals Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,991
30 Day Avg. Volume6,912
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.10Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FTXH Summary
FTXH is the First Trust Nasdaq Pharmaceuticals ETF, which follows the Nasdaq US Smart Pharmaceuticals Index. It invests mainly in U.S. drugmakers, from large, well-known companies like Johnson & Johnson and Pfizer to other major pharmaceutical firms. Someone might consider this ETF if they want focused exposure to the potential growth of new medicines, treatments, and long-term health care demand, while spreading money across many pharma stocks instead of picking just one. A key risk is that it is heavily concentrated in pharmaceutical companies, so its price can swing with drug trial results, regulation changes, and health care policy.
How much will it cost me?The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized sector, which typically involves more research and management costs.
What would affect this ETF?The FTXH ETF could benefit from advancements in pharmaceutical research, including breakthroughs in drug development and personalized medicine, as well as increased demand for innovative health care solutions in the U.S. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact the profitability of its top holdings like AbbVie, Johnson & Johnson, and Merck.
FTXH Top 10 Holdings
FTXH is very much a U.S. pharma story, with performance driven by a tight cluster of big drugmakers. Eli Lilly is still a key engine, rising recently and helping to pull the fund higher, while Merck and Johnson & Johnson provide steady, blue-chip ballast. Viatris has been quietly climbing and adds a bit of extra lift. On the flip side, AbbVie has been more mixed, and Regeneron has been losing steam, acting as a bit of a drag. Overall, this ETF is heavily concentrated in large U.S. pharmaceutical names, for better or worse.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 7.15% | $2.45M | $1.00T | 49.22% | 72 Outperform | |
| Merck & Company | 6.89% | $2.36M | $302.33B | 57.78% | 80 Outperform | |
| Bristol-Myers Squibb | 6.87% | $2.36M | $121.42B | 26.92% | 78 Outperform | |
| Johnson & Johnson | 6.86% | $2.35M | $564.11B | 53.22% | 78 Outperform | |
| AbbVie | 6.80% | $2.33M | $381.10B | 17.70% | 66 Neutral | |
| Viatris | 4.37% | $1.50M | $19.39B | 100.84% | 60 Neutral | |
| Biogen | 3.95% | $1.35M | $28.61B | 54.01% | 74 Outperform | |
| Pfizer | 3.55% | $1.22M | $147.62B | 11.06% | 74 Outperform | |
| Regeneron | 3.51% | $1.20M | $66.98B | 8.59% | 78 Outperform | |
| Gilead Sciences | 3.44% | $1.18M | $166.82B | 25.14% | 78 Outperform |
FTXH Technical Analysis
Positive
―
Price Trends
33.98
Positive
34.11
Positive
31.86
Positive
Market Momentum
0.09
Negative
59.69
Neutral
78.76
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTXH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.05, equal to the 50-day MA of 33.98, and equal to the 200-day MA of 31.86, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 59.69 is Neutral, neither overbought nor oversold. The STOCH value of 78.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTXH.
FTXH Peer Comparison
Comparison Results
Performance Comparison
FTXH
First Trust Nasdaq Pharmaceuticals ETF
34.87
9.74
38.76%
MILN
Global X Millennial Consumer ETF
―
―
―
GXPT
Global X PureCap MSCI Information Technology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents